Your browser doesn't support javascript.
loading
The Impact on Survival of Neoadjuvant Treatment Interruptions in Locally Advanced Rectal Cancer Patients.
Lișcu, Horia-Dan; Antone-Iordache, Ionut-Lucian; Atasiei, Dimitrie-Ionuț; Anghel, Ioana Valentina; Ilie, Andreea-Teodora; Emamgholivand, Taraneh; Ionescu, Andreea-Iuliana; Șandru, Florica; Pavel, Christopher; Ultimescu, Flavia.
Afiliación
  • Lișcu HD; Discipline of Oncological Radiotherapy and Medical Imaging, "Carol Davila" University of Medicine and Pharmacy, 050474 Bucharest, Romania.
  • Antone-Iordache IL; Radiotherapy Department, Colțea Clinical Hospital, 030167 Bucharest, Romania.
  • Atasiei DI; Discipline of Oncological Radiotherapy and Medical Imaging, "Carol Davila" University of Medicine and Pharmacy, 050474 Bucharest, Romania.
  • Anghel IV; Discipline of Oncological Radiotherapy and Medical Imaging, "Carol Davila" University of Medicine and Pharmacy, 050474 Bucharest, Romania.
  • Ilie AT; Discipline of Oncological Radiotherapy and Medical Imaging, "Carol Davila" University of Medicine and Pharmacy, 050474 Bucharest, Romania.
  • Emamgholivand T; Discipline of Oncological Radiotherapy and Medical Imaging, "Carol Davila" University of Medicine and Pharmacy, 050474 Bucharest, Romania.
  • Ionescu AI; Discipline of Oncological Radiotherapy and Medical Imaging, "Carol Davila" University of Medicine and Pharmacy, 050474 Bucharest, Romania.
  • Șandru F; Discipline of Oncological Radiotherapy and Medical Imaging, "Carol Davila" University of Medicine and Pharmacy, 050474 Bucharest, Romania.
  • Pavel C; Medical Oncology Department, Colțea Clinical Hospital, 030167 Bucharest, Romania.
  • Ultimescu F; Department of Dermatology, Elias University Emergency Hospital, 011461 Bucharest, Romania.
J Pers Med ; 14(3)2024 Feb 29.
Article en En | MEDLINE | ID: mdl-38541008
ABSTRACT
The standard oncologic treatment of locally advanced rectal cancer is long-course radio-chemotherapy followed by surgery and adjuvant chemotherapy. This can result in a lengthy total treatment duration, sometimes up to one year from the diagnosis. Interruptions to neoadjuvant treatment can occur for a variety of reasons, forced or unforced. The main purpose of this study is to analyze the survival data of locally advanced rectal cancer patients who received neoadjuvant treatment and to find a cut-off point showing exactly how many days of interruption of neoadjuvant treatment the risk of death or disease relapse increases. We conducted a retrospective study on 299 patients with locally advanced rectal cancer using survival analysis (Kaplan-Meier curve and Cox regression) to determine survival probabilities for overall survival, local control, and disease-free survival. Patients with 0 to 3 days of neoadjuvant therapy interruption had a higher overall survival probability compared to patients with 4 or more days (90.2% compared to 57.9%, p-value < 0.001), hazard ratio 5.89 (p < 0.001). Local control and disease-free survival had a higher probability in patients with 0-2 days of interruption compared to people with 3 or more days (94% vs. 75.4%, and 82.2% vs. 50.5%, respectively, both p-values < 0.001). Patients with tumoral or nodal downstaging experienced fewer days of interruption than patients with no downstage. These findings reinforce the need for radiation oncologists to be well-organized when starting neoadjuvant treatment for rectal cancer, in order to anticipate and prevent potential treatment interruptions and achieve the best therapeutic results.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: J Pers Med Año: 2024 Tipo del documento: Article País de afiliación: Rumanía Pais de publicación: Suiza

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: J Pers Med Año: 2024 Tipo del documento: Article País de afiliación: Rumanía Pais de publicación: Suiza